Spyre Therapeutics, Inc. SYRE Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s other income, net (note 6)?
- Spyre Therapeutics, Inc. (SYRE) reported other income, net (note 6) of -$30.36M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
- Spyre Therapeutics, Inc.'s other income, net (note 6) decreased by 1428.0% year-over-year, from $2.29M to -$30.36M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other income, net (note 6)?
- Over 3 years (2021 to 2024), Spyre Therapeutics, Inc.'s other income, net (note 6) has grown at a 453.7% compound annual growth rate (CAGR), from -$122K to -$20.71M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.